Christoph J. Bender

Dr. Christoph J. Bender focuses his practice on capital markets transactions and general securities-related matters.

Dr. Bender’s experience includes advising:

Capital Markets (Equity)

• Axian Telecom in its acquisition of 19.7 million ordinary shares from Jumia Technologies AG, representing 8% of Jumia’s outstanding share capital

• Jefferies and BofA Securities as joint global coordinators and joint bookrunners in connection with a capital increase of Zur Rose Group AG

Capital Markets (Equity-Linked/Debt)

• AGRAVIS Raiffeisen AG on multiple issuance of participation rights

Mergers and Acquisitions

• CureVac N.V. in its all-stock acquisition by BioNTech SE that values CureVac N.V. at US$1.25 billion
• the management and supervisory boards of Fresenius in the company’s exit from the Austrian and international businesses of VAMED AG
• Armira and Boxine on Boxine’s €1 billion business combination with 468 SPAC I SE, one of the first de-SPAC transactions in the market involving a German-listed blanc cheque company
• SIGNA Sports United GmbH in connection with its US$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group